Effect of perioperative flurbiprofen axetil on long-term survival of patients with esophageal carcinoma who underwent thoracoscopic esophagectomy: A retrospective study

Yanhu Xie PhD1,2 | Di Wang PhD1,2 | Chen Gao MS1,2 | Jicheng Hu MS1,2 | Min Zhang PhD1,2 | Wei Gao PhD1,2 | Shuhua Shu MS1,2 | Xiaoqing Chai BS1,2

1Department of Anesthesiology, Anhui Provincial Hospital, Hefei, Anhui, China
2Division of Life Sciences and Medicine, The First Affiliated Hospital of University of Science and Technology of China, University of Science and Technology of China, Hefei, Anhui, China

Correspondence
Xiaoqing Chai, Department of Anesthesiology, Anhui Provincial Hospital, Hefei, 230001 Anhui, China.
Email: xqc13805518889@163.com

Funding information
Anhui Provincial Key Research and Development Project Foundation, Grant/Award Number: 1804H08020286

Abstract

Background and Objectives: Nonsteroidal anti-inflammatory drugs (NSAIDs) have an anti-inflammatory response, but it remains unclear whether the perioperative use of flurbiprofen axetil can influence postoperative tumor recurrence and survival in esophageal carcinoma. We aimed to explore the effect of perioperative intravenous flurbiprofen axetil on recurrence-free survival (RFS) and overall survival (OS) in patients with esophageal carcinoma who underwent thoracoscopic esophagectomy.

Methods: This retrospective study included patients who underwent surgery for esophageal carcinoma between December 2009 and May 2015 at the Department of Thoracic Surgery, Anhui Provincial Hospital. Patients were categorized into a non-NSAIDs group (did not receive flurbiprofen axetil), single-dose NSAIDs group (received a single dose of flurbiprofen axetil intravenously), and multiple-dose NSAIDs group (received multiple doses of flurbiprofen).

Results: A total of 847 eligible patients were enrolled. Univariable and multivariable analyses revealed that the intraoperative use of flurbiprofen was associated with long-term RFS (hazard ratio [HR]: 0.56, 95% confidence interval [CI]: 0.42–0.76, \( p = .001 \)) and prolonged OS (HR: 0.49, 95% CI: 0.38–0.63, \( p = .001 \)).

Conclusions: Perioperative flurbiprofen axetil therapy may be associated with prolonged RFS and OS in patients with esophageal carcinoma undergoing thoracoscopic esophagectomy.

KEYWORDS
esophageal carcinoma, flurbiprofen axetil, NSAIDs, OS, RFS, thoracoscopic surgery
1 | INTRODUCTION

Esophageal carcinoma, the fourth most common malignancy in China,1 is characterized by a high degree of locoregional recurrence, distant metastases, and poor overall survival (OS).2,3 Being the sixth most common cause of cancer-related mortalities, it accounts for an estimated 400,000 cases (4.9%) of death worldwide.1 Reportedly, approximately 80% of new cases occur in less-developed regions of the world, out of which about 60% of them occur in China.5 Among the two dominant histologic subtypes (esophageal adenocarcinoma and esophageal squamous cell carcinoma [ESCC]),1 ESCC remains the main subtype with approximately 90% of cases occurring in the Asia-Pacific region, including China.6 China presents a high incidence of esophageal carcinoma, especially in rural regions. Furthermore, higher incidence rates of ESCC have been reported in different provinces of China, including Hebei, Henan, Fujian, and Chongqing, followed by Xinjiang, Jiangsu, Shanxi, Gansu, and Anhui,7 with recognized hotspots in Liaoning (Hebei province) and Cixian county, and near Taihang Mountains.8,9 The profound heterogeneity of etiological risk factors underlying esophageal carcinoma is particularly compelling. Despite its rapidly progressive course, the involvement of modifiable risk factors in conjunction with late-stage presentation highlights the scope for better management of the disease.10 Several decades of extensive research in the high-risk areas of China have provided novel insights on the epidemiology, etiology, early detection,11 and management of this disease.12–17 However, despite recent advances in the diagnosis and treatment of this neoplastic condition, failure of chemotherapy and radiotherapy leads to tumor recurrence and poor prognosis. This could be mainly due to its aggressive nature and the limited efficiency of treatment modalities.18

Currently, esophagectomy is the mainstay of treatment for patients with resectable esophageal carcinoma, although distant control and complete resection rate continue to remain a challenge.19,20 Nevertheless, the overall 5-year survival rate after esophagectomy remains about 21% in China.21 This dismal result could be attributed to recurrence after resection of the primary tumor. Locoregional recurrences or/and distant organ metastases were found in approximately 50% of patients within 2–3 years of surgery.22–24 The recurrence patterns following esophagectomy have been well-studied.22,24,25 Factors such as histologic tumor depth invasion,22,24 local-regional lymph node metastases,24 and intramural metastasis25 have been shown to predict tumor recurrence. Of note, recent improvements in perioperative management have reduced postoperative mortality to acceptable levels. However, the perioperative period is highly vulnerable to the development of metastases, including the accelerated growth of micrometastatic disease and increased formation of new metastatic foci.26 Several factors, including profound depression of antitumoral cellular immunity, may contribute to this phenomenon.27 In addition, during the perioperative period per se, the immune function of patients could be influenced by the anesthesia management; volatile anesthetics and opioids might worsen the immunosuppression and thereby exacerbate long-term outcome, while local anesthetics and nonsteroidal anti-inflammatory drugs (NSAIDs) might diminish the immunosuppression and exert beneficial effects.28–30 Moreover, the perioperative use of β-adrenoceptor antagonists, NSAIDs, intravenous anesthetics, and antithrombotic agents has been linked with improved survival outcomes in patients with neoplasms.27,31 Furthermore, NSAIDs have been shown to minimize postoperative opioid consumption and further aid the strengthening of the cell-mediated immune competence.32 Collectively, these findings indicate that perioperative management is crucial as it may contribute to the long-term outcome of patients after surgery. Still, the degree of pain after thoracic surgery is very high.33–35 In the absence of standardized treatment, acute pain will turn into chronic pain in more than 30% of the patients,36–38 affecting the patient’s quality of life and cooperation. Hence, analgesia must be used, but carefully and keeping oncological safety in mind.

A previous retrospective study in 327 women who underwent mastectomy for breast cancer demonstrated that the intraoperative administration of ketorolac (NSAID) significantly reduces the risk of breast cancer relapse compared with other analgesics (sufentanil, ketamine, and clonidine).27 Furthermore, another recent study showed that the perioperative use of dexamethasone with/without flurbiprofen axetil is associated with longer survival in patients who underwent surgery for non-small-cell lung carcinoma (NSCLC).27 Flurbiprofen axetil, an injectable produg of flurbiprofen,39 is a nonselective cyclooxygenase inhibitor used as an NSAID.40,41 It is widely used for postoperative pain relief.42 A study by Tedore et al.43 showed that flurbiprofen exerts its analgesic effect by inhibiting prostaglandin (PG) synthesis. Nevertheless, the effect of perioperative use of NSAIDs, especially flurbiprofen, on the long-term survival of patients with ESCC still remains elusive. Furthermore, it is unclear whether the perioperative use of flurbiprofen has an impact on the postoperative recurrence after surgery for esophageal cancer.

Therefore, in view of the above and the association between flurbiprofen and long-term survival is uncertain, this study aimed to investigate the effect of perioperative intravenous flurbiprofen axetil on recurrence-free survival (RFS) and OS in Chinese patients with esophageal carcinoma who underwent thoracoscopic esophagectomy.

2 | MATERIALS AND METHODS

2.1 | Patient population

This retrospective study included consecutive patients with esophageal carcinoma who underwent thoracoscopic esophagectomy between December 2009 and May 2015 at the Department of Thoracic Surgery, Anhui Provincial Hospital, Hefei, China. All patients aged 50 years or older with complete clinical data were included in this study. The exclusion criteria were: (1) patients with severe impairment of pulmonary and cardiac functions during preoperative evaluation (New York Heart Association classes III/IV);
(2) patients with severe postoperative complications, such as anastomotic fistula, bleeding, infection, and other life-threatening complications; (3) patients whose postoperative histopathological results revealed benign tumors; (4) patients with incomplete or missing clinical data or whose follow-up contact information is unavailable, or whose family members declined to participate in the follow-up survey; (5) patients who underwent palliative surgery for secondary malignancies. This study was approved by the Biomedical Ethics Committee of Anhui Medical University and was registered in the Chinese Clinical Trial Registry (ChiCTR-IPR-15006482). The informed consent of patients was waived by the committee owing to the retrospective design of the study.

2.2 | Data collection

Demographic and perioperative data for all patients with esophageal carcinoma were retrieved from the medical record database of Anhui Provincial Hospital. The collected data included age, gender, body mass index, preoperative baseline blood pressure and heart rate, American Society of Anesthesiologists’ physical status, stage of the tumor, the extent of lymph node invasion and metastasis, type of tumor histology, comorbidities, history of administered NSAIDs, and perioperative data (infusion of propofol, remifentanil, and the duration of surgery).

2.3 | Groups and NSAID administration

Since not all doctors at the authors’ center use flurbiprofen for analgesia during the perioperative period, some patients did not receive flurbiprofen during the perioperative period. Therefore, the patients who received or did not receive perioperative flurbiprofen during the same period could be included. According to the number of flurbiprofen axetil, patients were categorized into three groups as follows: non-NSAIDs (did not receive flurbiprofen axetil), single-dose NSAIDs (patients received 100 mg of flurbiprofen axetil [50 mg/5 ml]; H20041508; Beijing Tide Pharmaceutical Co., Ltd.) intravenously before induction of anesthesia], and multiple-dose NSAIDs (patients received a dose of 100 mg of flurbiprofen axetil intravenously before induction of anesthesia and an infusion of flurbiprofen axetil [50 mg/12 h] twice a day for 2 days on the second day after surgery). Standardized anesthetic techniques were carried out, and flurbiprofen axetil was received under general anesthesia in all patients.

2.4 | Endpoints

The primary endpoint of this study is RFS and OS. RFS was defined as the time (in months) from the date of surgery until the first recurrence or death due to oncological cause, whichever occurred first. OS was defined as the time from the date of surgery until death due to any cause. Recurrence was defined as clinical evidence of local recurrence or metastases on radiological examination.

2.5 | Follow-up

The survival data of all patients were collected by telephonic interview using a structured questionnaire, including short-term comorbidity information, such as gastrointestinal distress, cardiovascular events, and respiratory complications. Postsurgery, patients were followed tri-monthly for the first 2 years, then twice a year for 3 years, and annually thereafter. Patients were censored if they were lost in follow-up or remained disease-free at the end of follow-up.

2.6 | Statistical analyses

Data were analyzed by using the SPSS statistical software (Version 16.0, SPSS Inc.). The Kolmogorov–Smirnov test was applied to assess the normality of continuous data. The continuous data with normal distribution or non-normal distribution are presented as mean ± SD or median (range). For continuous data with normal distribution, one-way analysis of variance was used to compare the means of groups, and the LSD test was used for further pair-wise comparison, while for continuous data with nonnormally distributed, the Kruskal–Wallis test was performed to compare variables between different groups and determine the statistical significance. Categorical data are expressed in count (percentage), and statistical significance was determined by using the χ² or Fisher’s exact test. Univariable Cox models were used to assess the potential impact of different baseline characteristics on the outcome. Multivariable Cox proportional hazards models were then applied after adjusting for any baseline factors and intraoperative or oncological factors related to the outcome in the univariable analysis. Factors that were possibly associated with the outcomes (set as p ≤ .10 in univariable analysis or were regarded as clinically important) were included in the Cox proportional hazards models for multivariable analysis to identify independent factors that were associated with RFS and OS (p < .05). The Kaplan–Meier analyses were used to estimate RFS and OS probabilities. The log rank test was used for the comparison of RFS and OS between the NSAID (single- and multiple-dose NSAIDs) and the non-NSAID (Group A) groups or single- and multiple-dose NSAIDs group. Two-sided p < .05 were considered statistically significant.

3 | RESULTS

3.1 | General information

In this study, we retrospectively reviewed the clinical data of a total of 1182 patients. Among these, 335 patients were excluded,
including 131 patients who showed severe impairment of pulmonary and cardiac functions before surgery, 43 patients died within 30 days of surgery due to severe complications (anastomotic fistula, bleeding, infection, lung embolism, acute cardio infarction). 98 patients who either declined a telephonic interview or whose contact information was unavailable, 63 patients showed nonmalignant postoperative histopathology. Finally, a total of 847 patients who met the inclusion criteria were included in our analyses (Figure 1). Among these, the non-NSAIDs group comprised 169 patients and the groups that received flurbiprofen axetil comprised 678 patients. Out of these 678 patients, 544 patients received a single preoperative dose of flurbiprofen axetil (single-dose NSAIDs), whereas 134 patients received multiple doses of flurbiprofen axetil (multiple-dose NSAIDs). Table 1 summarizes baseline patient characteristics, tumor histopathological features, and perioperative data of the three groups. The mean ages of patients in the non-NSAIDs, single-dose NSAIDs, and multiple-dose NSAIDs group were 62.54 ± 9.19, 63.43 ± 8.35, and 63.04 ± 8.83, respectively. Notably, significant differences with respect to esophageal cancer staging and tumor type (squamous cell carcinoma [SCC] and adenocarcinoma) were observed between the non-NSAIDs group and the groups that received perioperative intravenous flurbiprofen axetil (single-dose NSAIDs and multiple-dose NSAIDs group) (p = .019 and p = .001, respectively).

3.2 | Comparison analyses of RFS and OS between controls and the groups that received flurbiprofen

The intraoperative administration of flurbiprofen, either as a single dose or multiple doses, was found to be associated with long-term RFS and OS (p < .001) (Figure 2A,B). Four factors that were identified by univariable analyses were included in the multivariable Cox proportional hazards model. Multivariable analysis identified three independent factors, among them increasing tumor stage (hazard ratio [HR]: 1.58, 95% confidence interval [CI]: 1.32–1.88, p = .001), lymph node invasion (HR: 1.51, 95% CI: 1.3–1.76, p = .001) were found to be significant risk factors affecting RFS in patients. Furthermore, the intraoperative administration of flurbiprofen (HR: 0.56, 95% CI: 0.42–0.76, p = .001) was found to be protective factors associated with long-term RFS in these patients (Table 2).

Six factors that were identified by univariable analyses were included in the multivariable Cox proportional hazards model. Multivariable analysis identified four independent factors. Among them, increasing tumor stage (HR: 1.49, 95% CI: 1.28–1.74, p = .001), lymph node invasion (HR: 1.63, 95% CI: 1.43–1.85, p = .001), age (HR: 1.03, 95% CI: 1.01–1.05, p = .001) were associated with shortened OS. On the contrary, the perioperative use of flurbiprofen axetil (HR: 0.49, 95% CI: 0.38–0.63, p = .001) was found to be associated with prolonged OS (Table 3).

3.3 | Comparison analyses of RFS and OS between single-dose NSAID group and multiple-dose NSAID group

Interestingly, there was no significant difference between the RFS of patients who received a single dose of flurbiprofen and that of those who received multiple doses (Figure 2C). Similarly, the frequency of flurbiprofen dosage was not found to influence the OS in these patients (Figure 2D). Three factors that were identified by univariable analyses were included in the multivariable Cox proportional hazards model. Multivariable analysis revealed increasing tumor stage (HR: 1.64, 95% CI: 1.33–2.03, p < .001) and lymph node invasion (HR: 1.51, 95% CI: 1.26–1.78, p < .001) to be significant risk factors affecting RFS in these patients (Table 4).
All factors that were identified by univariable analyses were found to be independently associated with OS in multivariable analysis. Expectedly, increasing tumor stage (HR: 1.54, 95% CI: 1.28–1.85, p = .001), lymph node invasion (HR: 1.62, 95% CI: 1.40–1.89, p = .001), age (HR: 1.03, 95% CI: 1.01–1.05, p = .001) were associated with shortened OS (Table 5).

## TABLE 1 Characteristics of patients and perioperative procedure

| Variable                        | Non-NSAIDs (n = 169) | NSAIDs (n = 678) | Multiple does NSAIDs (n = 134) | p Value |
|---------------------------------|----------------------|------------------|-------------------------------|---------|
|                                 |                      | Single does NSAIDs (n = 544) |                      |         |
| Age (years)                     | 62.54 ± 9.19         | 63.43 ± 8.35     | 63.04 ± 8.83                 | .490    |
| Gender                          | 139/30               | 427/117          | 106/28                       | .573    |
| SBP (mmHg)                      | 130.33 ± 16.86       | 131.07 ± 15.84   | 129.66 ± 11.98               | .604    |
| DBP (mmHg)                      | 78.18 ± 9.13         | 78.35 ± 9.12     | 77.75 ± 7.88                 | .779    |
| Heart rate (bpm)                | 76.11 ± 8.34         | 75.85 ± 9.28     | 76.04 ± 8.75                 | .935    |
| BMI (kg/m²)                     | 22.49 ± 2.85         | 22.53 ± 9.61     | 22.59 ± 2.97                 | .995    |
| ASA grade                       |                      |                  |                               |         |
| I                               | 6 (4%)               | 9 (2%)           | 4 (3%)                       |         |
| II                              | 130 (77%)            | 443 (81%)        | 95 (71%)                     |         |
| III                             | 33 (19%)             | 92 (17%)         | 35 (26%)                     |         |
| Tumor stagea                    |                      |                  |                               | .019*   |
| I                               | 4 (2%)               | 19 (3%)          | 4 (3%)                       |         |
| II                              | 18 (11%)             | 70 (13%)         | 9 (7%)                       |         |
| III                             | 40 (24%)             | 142 (26%)        | 34 (25%)                     |         |
| IV                              | 97 (57%)             | 243 (45%)        | 77 (57%)                     |         |
| V                               | 10 (6%)              | 70 (13%)         | 10 (8%)                      |         |
| Lymph node invasiona            |                      |                  |                               | .460    |
| I                               | 108 (64%)            | 319 (59%)        | 82 (61%)                     |         |
| II                              | 41 (24%)             | 141 (26%)        | 31 (23%)                     |         |
| III                             | 18 (11%)             | 64 (12%)         | 19 (14%)                     |         |
| IV                              | 2 (1%)               | 20 (3%)          | 2 (2%)                       |         |
| Metastases                      |                      |                  |                               | .469    |
| Yes                             | 2 (1%)               | 9 (2%)           | 4 (3%)                       |         |
| No                              | 167 (99%)            | 535 (98%)        | 130 (97%)                    |         |
| Tumor type                      |                      |                  |                               | .001*   |
| Squamous cell carcinoma         | 33 (20%)             | 420 (77%)        | 27 (20%)                     |         |
| Adenocarcinoma (glandular cells)| 136 (80%)            | 124 (23%)        | 107 (80%)                    |         |

Note: Continuous variables with a normal distribution (age, SBP, DBP, heart rate, BMI) are presented as mean ± standard deviation. Categorical variables are expressed as frequency or percentage. Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; DBP, diastolic blood pressure; NSAIDs, nonsteroidal anti-inflammatory drugs; SBP, systolic blood pressure.

*Tumor stage and lymph node invasion classification reference from TNM-7th Edition 2009 (UICC/AJCC) and Japanese Classification 2010 in Gastric Cancer.

* p < .05 was considered significant.

**DISCUSSION**

This retrospective study demonstrated an association between the perioperative administration of flurbiprofen and a reduced risk of recurrence after surgery for esophageal carcinoma. Similarly, an apparent association was found between the
Our findings were consistent with the results of previous studies that demonstrated significant associations between the perioperative use of NSAIDs and survival outcomes (RFS and OS) of patients who underwent surgery for breast cancer and NSCLC. On the contrary, we observed that there were no significant differences in RFS and OS of patients who received a single dose of flurbiprofen and that of those who received multiple doses. To the best of our knowledge, this is the first retrospective study to investigate and compare the effects of single and multiple doses of flurbiprofen on RFS and OS of Chinese patients who underwent thoracoscopic esophagectomy for esophageal carcinoma. Most importantly, our findings highlight the dose-independent effect of perioperative flurbiprofen axetil therapy, which may improve patients' long-term survival (RFS and OS) after thoracoscopic esophagectomy.

One of the most prominent prognostic factors affecting the treatment of esophageal cancer is lymph node metastasis. The presence and number of metastatic lymph nodes governing the lymph node status have been shown to be independent predictors for long-term survival. Lymph node metastasis has been shown to be associated with poor survival, whereby an increasing number of metastatic lymph nodes predicted a progressively poor prognosis. Reportedly, the 5-year survival rate for patients with lymph node metastasis is quite low. On average, patients with a single lymph node metastasis showed a significantly longer survival compared with those having two or more lymph node metastases. Similarly, a study by Zhang et al. demonstrated a significant association of the number of positive lymph nodes with survival in patients with esophageal SCC and further showed that patients with 0, 1, and ≥2 positive nodes had 5-year survival rates of 59.8%, 33.4%, and 9.4%, respectively. Consistent with the previous literature, in

FIGURE 2 Comparison of survival curves (recurrence-free survival [RFS] and overall survival [OS]) among the three groups. Kaplan–Meier curves for the (A) RFS and (B) OS among patients who received perioperative flurbiprofen as compared with those who did not receive the NSAID (non-NSAIDs group). Kaplan–Meier curves for the (C) RFS and (D) OS among patients who received a single dose of perioperative flurbiprofen (single-dose NSAIDs group) as compared with those who received multiple doses of the NSAID (multiple-dose NSAIDs groups). NSAIDs, nonsteroidal anti-inflammatory drugs [Color figure can be viewed at wileyonlinelibrary.com]
In this study, we demonstrated that the extent of lymph node invasion significantly affected the RFS or OS and was found to be significantly associated with shortened survival in patients who did not receive a perioperative intravenous infusion of flurbiprofen axetil. The patients’ RFS and OS were improved by flurbiprofen axetil used in perioperative; however, multiple-dose of flurbiprofen axetil cannot again extend the RFS or OS of patients who underwent surgery for esophageal carcinoma. Taken together, this study suggests that both the status of lymph nodes and the nature of a tumor need to be evaluated for optimal treatment decisions.

### TABLE 2

| Variable                   | Univariate analyses | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | HR                  | 95% CI                | p Value | HR                  | 95% CI                | p Value |
| No vs. NSAIDs              | 0.608               | 0.452–0.817           | .001*   | 0.562               | 0.418–0.756           | .001*   |
| Age (years)                | 1.004               | 0.988–1.020           | .644    | –                   | –                     | –       |
| Gender                     | 0.940               | 0.669–1.322           | .723    | –                   | –                     | –       |
| SBP (mmHg)                 | 1.003               | 0.994–1.012           | .541    | –                   | –                     | –       |
| DBP (mmHg)                 | 1.001               | 0.986–1.017           | .849    | –                   | –                     | –       |
| Heart rate (bpm)           | 1.004               | 0.989–1.019           | .572    | –                   | –                     | –       |
| BMI (kg/m²)                | 0.974               | 0.927–1.022           | .279    | –                   | –                     | –       |
| ASA grade                  | 1.065               | 0.773–1.466           | .701    | –                   | –                     | –       |
| Tumor stage                | 1.684               | 1.424–1.992           | .001*   | 1.577               | 1.322–1.882           | .001*   |
| Lymph node invasion        | 1.643               | 1.419–1.903           | .001*   | 1.515               | 1.300–1.765           | .001*   |
| Metastases                 | 1.282               | 0.477–3.450           | .622    | –                   | –                     | –       |
| Tumor type                 | 0.621               | 0.474–0.816           | .001*   | –                   | –                     | –       |
| Complications              | 0.966               | 0.734–1.270           | .803    | –                   | –                     | –       |

Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; HR, hazard ratio; NSAIDs, nonsteroidal anti-inflammatory drugs; RFS, recurrence-free survival; SBP, systolic blood pressure. *p < .05 was considered significant.

### TABLE 3

| Variable                   | Univariate analyses | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | HR                  | 95% CI                | p Value | HR                  | 95% CI                | p Value |
| No vs. NSAIDs              | 0.571               | 0.445–0.733           | .001*   | 0.492               | 0.382–0.634           | .001*   |
| Age (years)                | 1.030               | 1.015–1.045           | .001*   | 1.029               | 1.014–1.045           | .001*   |
| Gender                     | 0.843               | 0.625–1.139           | .266    | –                   | –                     | –       |
| SBP (mmHg)                 | 1.007               | 0.999–1.015           | .069    | –                   | –                     | –       |
| DBP (mmHg)                 | 0.996               | 0.983–1.009           | .552    | –                   | –                     | –       |
| Heart rate (bpm)           | 1.005               | 0.992–1.018           | .465    | –                   | –                     | –       |
| BMI (kg/m²)                | 0.994               | 0.968–1.021           | .649    | –                   | –                     | –       |
| ASA grade                  | 1.198               | 0.917–1.566           | .185    | –                   | –                     | –       |
| Tumor stage                | 1.652               | 1.431–1.908           | .001*   | 1.494               | 1.284–1.739           | .001*   |
| Lymph node invasion        | 1.712               | 1.514–1.936           | .001*   | 1.625               | 1.427–1.849           | .001*   |
| Metastases                 | 1.695               | 0.800–3.588           | .168    | –                   | –                     | –       |
| Tumor type                 | 0.630               | 0.499–0.795           | .001*   | –                   | –                     | –       |
| Complications              | 0.764               | 0.606–0.964           | .023*   | 0.812               | 0.636–1.037           | .095    |

Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; HR, hazard ratio; NSAIDs, nonsteroidal anti-inflammatory drugs; OS, overall survival; SBP, systolic blood pressure. *p < .05 was considered significant.
Staging in esophageal cancer depends on the depth of tumor invasion, involvement of regional lymph nodes, and the presence or absence of metastasis. In this study, we showed that the tumor stage could have a significant impact on both the OS and RFS of patients who did not receive a perioperative intravenous infusion of flurbiprofen axetil.

Emerging evidence suggests that the perioperative timeframe is a crucial facilitator of metastatic progression, with several variables showing significant associations with prognosis. Table 4 presents the univariate and multivariate analyses of prognostic factors associated with RFS in single-dose NSAIDs and multiple-dose NSAIDs groups.

Table 5 provides similar analyses for OS, highlighting the importance of tumor stage, lymph node invasion, and metastases in predicting survival outcomes.

**Table 4** Univariate and multivariate analyses of prognostic factors associated with RFS in single-dose NSAIDs and multiple-dose NSAIDs groups

| Variable                | Univariate analyses | Multivariate analysis |
|-------------------------|---------------------|----------------------|
|                         | HR 95% CI           | p Value              | HR 95% CI           | p Value              |
| Single-dose vs. multiple| 0.933 0.624–1.395   | .735                 | -                    | -                    |
| Age (years)             | 1.013 0.994–1.033   | .186                 | -                    | -                    |
| Gender                  | 0.952 0.638–1.422   | .810                 | -                    | -                    |
| SBP (mmHg)              | 1.003 0.992–1.013   | .644                 | -                    | -                    |
| DBP (mmHg)              | 0.995 0.977–1.013   | .585                 | -                    | -                    |
| Heart rate (bpm)        | 1.005 0.987–1.022   | .615                 | -                    | -                    |
| BMI (kg/m²)             | 0.957 0.901–1.016   | .152                 | -                    | -                    |
| ASA grade               | 1.176 0.803–1.722   | .406                 | -                    | -                    |
| Tumor stage             | 1.800 1.470–2.205   | <.001*               | 1.643 1.331–2.028   | <.001*               |
| Lymph node invasion     | 1.697 1.433–2.009   | <.001*               | 1.507 1.263–1.797   | <.001*               |
| Metastases              | 1.169 0.373–3.669   | .789                 | -                    | -                    |
| Tumor type              | 0.695 0.484–1.000   | .050*                | -                    | -                    |
| Complications           | 0.978 0.707–1.353   | .891                 | -                    | -                    |

**Table 5** Univariate and multivariate analyses of prognostic factors associated with OS in single-dose NSAIDs and multiple-dose NSAIDs groups

| Variable                | Univariate analyses | Multivariate analysis |
|-------------------------|---------------------|----------------------|
|                         | HR 95% CI           | p Value              | HR 95% CI           | p Value              |
| Single-dose vs. multiple| 0.886 0.628–1.249   | .489                 | -                    | -                    |
| Age (year)              | 1.031 1.013–1.049   | .001*                | 1.031 1.013–1.049   | 0.001*               |
| Gender                  | 0.817 0.569–1.173   | .274                 | -                    | -                    |
| SBP (mmHg)              | 1.005 0.996–1.014   | .313                 | -                    | -                    |
| DBP (mmHg)              | 0.989 0.974–1.005   | .170                 | -                    | -                    |
| Heart rate (bpm)        | 1.007 0.992–1.023   | .375                 | -                    | -                    |
| BMI (kg/m²)             | 0.992 0.958–1.027   | .632                 | -                    | -                    |
| ASA grade               | 1.088 0.778–1.522   | .623                 | -                    | -                    |
| Tumor stage             | 1.748 1.468–2.081   | <.001*               | 1.546 1.288–1.856   | <.001*               |
| Lymph node invasion     | 1.774 1.538–2.047   | <.001*               | 1.624 1.397–1.887   | <.001*               |
| Metastases              | 1.823 0.809–4.111   | .148                 | -                    | -                    |
| Tumor type              | 0.784 0.569–1.081   | .138                 | -                    | -                    |
| Complications           | 0.787 0.595–1.042   | .094                 | -                    | -                    |

Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; DBP, diastolic blood pressure; NSAIDs, nonsteroidal anti-inflammatory drugs; RFS, recurrence-free survival; SBP, systolic blood pressure. p < .05 was considered significant.
deleterious processes, including excess and maladaptive perioperative responses operating at the paracrine, endocrine, and immunological levels. Several perioperative risk factors, such as shedding of malignant cells, accelerated malignant tissue proliferation and surgical stress induced due to catecholamines, PGs, and opiates/opioids, excessive release of proangiogenic/proinvasive factors, increased invasion capacity, the abundant release of growth factors, psychological distress, and suppression of CMI, secretion of vascular endothelial growth factor may act synergistically to initiate new metastases and facilitate the outbreak of pre-existing micrometastases, thus impacting the long-term recurrence rates in patients with esophageal carcinoma.

Substantive clinical and epidemiological evidence indicates that the increase in the levels of proinflammatory mediators, such as cytokines, chemokines, and PGs in solid tumors, has become a major risk factor for cancer development. A review of the literature reveals that PGs, especially prostaglandin E2 (PGE2), produced by COX-2 (a member of the cyclooxygenase enzyme family), promote neoplastic progression. The role of COX-2 in carcinogenesis, especially in cell proliferation, apoptosis inhibition, angiogenesis, invasiveness, and immunosuppression, has been well-studied. Furthermore, the overexpression of COX-2 was found to be significantly associated with the depth of invasion, lymph node metastasis, distant metastasis, and TNM stage in esophageal cancer. Moreover, a number of the studies suggested that COX-2 overexpression was associated with a poor prognosis. A recent study indicated that perioperatively administered flurbiprofen inhibited COX-2 and PGE2 levels that in turn impaired the postoperative increase of programmed death 1 (PD-1) expression levels on circulating CD8+ T cells. Further, another study showed that circulating T cells (CD4+T and CD8+T cell) express upregulated levels of PD-1, which correlated with a poorer clinical outcome in patients with lung cancer. Of note, a large proportion of patients (14.5%–82.8%) with esophageal carcinoma harbor tumors with programmed death-ligand 1 (PD-L1) expression. A study by Hsieh et al. advocated that the overexpression of PD-L1 on cytoplasm is an independent prognostic factor for disease-free survival in patients who underwent esophagectomy for ESCC and further suggested that patients without overexpression of PD-L1 and PD-L2 had a better OS. PD-1 expression in tumor-infiltrating T cells and circulating T cells has been reported in several malignant tumors. In addition, the expression of PD-L1 (ligand for PD-1) has been linked with rapid cancer progression, higher recurrence rates, and worse survival. Corroborating the results of this study, these findings collectively indicate that perioperative flurbiprofen therapy may modify the immune-checkpoint expression and limit long-term cancer recurrence, thus improving the OS rates in patients undergoing esophagectomy for esophageal carcinoma.

Expectedly, in this study, multivariable analyses showed age to be independently associated with poorer survival in patients who did not receive perioperative flurbiprofen. After adjustment for the potential confounder (age), the association between perioperative flurbiprofen administration and the lower risk of cancer recurrence and prolonged survival remained significant. Advanced age is associated with poor outcomes following esophageal resection. Moreover, advanced age is considered a relative contraindication for flurbiprofen (and other NSAIDs) and consequently prompts a decreased usage of flurbiprofen in elderly patients. Therefore, the perioperative use of flurbiprofen in elderly patients with esophageal cancer after surgical resection can improve survival, but dose control and potential risk monitoring are essential.

In addition to the significant findings revealed by this study, there are some limitations currently study. Despite accessing high-quality electronic health record databases and considering all-known variables that could affect the outcome in our statistical analyses, a series of potential uncontrolled and unrecognized biases, such as selection bias, diagnostic bias, and bias in follow-up, which may confound the results were inevitable due to the inherent nature of this observational retrospective study. Furthermore, the single-center study design may limit the generalizability of the findings in this study. Moreover, the follow-up data regarding patients’ neoadjuvant chemotherapy, adjuvant radiation, or other adjuvant therapies were unavailable, which might influence the study’s endpoint. Third, study groups received either a single equivalent dose of intravenous flurbiprofen preoperatively or multiple doses of flurbiprofen with 100 mg both preoperatively and postoperatively (twice a day for 2 days). As the treatment was uniform, concerning the individual difference, individualized dosage regimens based on the patient’s status and the tumor nature need to be considered to minimize the potential bias.

5 CONCLUSIONS

In summary, this study demonstrated significant associations between the intraoperative administration of flurbiprofen and RFS and OS of Chinese patients who underwent thoracoscopic esophagectomy for esophageal carcinoma. The findings reported here showed new light on the effect of perioperative flurbiprofen axetil therapy, which may improve patients’ long-term survival after thoracoscopic esophagectomy. Further prospective randomized controlled trials for ascertaining the efficacy of perioperative flurbiprofen axetil, validating it as a useful adjuvant in the immune-checkpoint blockade therapy and further establishing it as a standard-of-care treatment in patients undergoing thoracoscopic esophagectomy are necessary.

ACKNOWLEDGMENTS

The authors would like to acknowledge the assistance of Meiqing Xu for his valuable advice related to surgery and the Department of Thoracic Surgery, Anhui Provincial Hospital. This study was supported by the Anhui Provincial Key Research and Development Project Foundation (No. 1804h08020286).

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.
AUTHOR CONTRIBUTIONS
Xiaqing Chai and Yanhu Xie were responsible for the study concept and design. Wei Gao, Yanhu Xie contributed to data collection. Di Wang and Jicheng Hu conducted the statistical analyses. Jicheng Hu and Di Wang drafted the manuscript and contributed to the interpretation of the results. Xiaqing Chai reviewed this manuscript. All authors approved the final manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author.

ORCID
Xiaqing Chai https://orcid.org/0000-0002-6176-6435

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
2. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062-5067.
3. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25:3719-3725.
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
5. Xie X, Liu K, Liu F, et al. Gossypetin is a novel MKK3 and MKK6 inhibitor that suppresses esophageal cancer growth in vitro and in vivo. Cancer Lett. 2019;442:126-136.
6. Zhao J, He YT, Zheng RS, Zhang SW, Chen WQ. Analysis of esophageal cancer time trends in China, 1989-2008. Asian Pac J Cancer Prev. 2012;13:4613-4617.
7. Zhou MG, Wang XF, Hu JP, et al. [Geographical distribution of cancer mortality in China, 2004-2005]. Zhonghua Yu Fang Yi Xue Za Zhi. 2010;44:303-308.
8. Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64:381-387.
9. Bray F, Ferlay J, Laversanne M, et al. Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration. Int J Cancer. 2015;137(1):2060-2071.
10. Murphy G, McCormack V, Abedi-Ardekani B, et al. International cancer seminars: a focus on esophageal squamous cell carcinoma. Ann Oncol. 2017;28:2086-2093.
11. Pan QJ, Roth MJ, Guo HQ, et al. Cytologic detection of esophageal squamous cell carcinoma and its precursor lesions using balloon samplers and liquid-based cytology in asymptomatic adults in Linxian, China. Acta Cytol. 2008;52:14-23.
12. Tran GD, Sun XD, Abnet CC, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2005;113:456-463.
13. Qiao YL, Dawsey SM, Kamangar F, et al. Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial. J Natl Cancer Inst. 2009;101:507-518.
14. Mark SD, Qiao YL, Dawsey SM, et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst. 2000;92:1753-1763.
15. Abnet CC, Qiao YL, Dawsey SM, Dong ZW, Taylor PR, Mark SD. Tooth loss is associated with increased risk of total death and death from upper gastrointestinal cancer, heart disease, and stroke in a Chinese population-based cohort. Int J Epidemiol. 2005;34:467-474.
16. Abnet CC, Qiao YL, Mark SD, Dong ZW, Taylor PR, Dawsey SM. Prospective study of tooth loss and incident esophageal and gastric cancers in China. Cancer Causes Control. 2001;12:847-854.
17. Wei WQ, Abnet CC, Qiao YL, et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. Am J Clin Nutr. 2004;79:80-85.
18. Zheng WB, Li YJ, Wang Y, et al. Propafenone suppresses esophageal cancer proliferation through inducing mitochondrial dysfunction. Am J Cancer Res. 2017;7:2245-2256.
19. Takeuchi H, Miyata H, Gotoh M, et al. A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database. Ann Surg. 2014;260:259-266.
20. Napier KJ, Scheerer M, Misra S. Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014;6:112-120.
21. Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003-2005: a population-based study. Int J Cancer. 2015;136:1921-1930.
22. Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198:205-211.
23. Chen G, Wang Z, Liu XY, Liu FY. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy. World J Surg. 2007;31:1107-1114.
24. Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer. 2003;97:1616-1623.
25. Kosugi S, Kanda T, Yajima K, Ishikawa T, Hatakeyama K. Risk factors that influence early death due to cancer recurrence after extended radical esophagectomy with three-field lymph node dissection. Ann Surg Oncol. 2011;18:2961-2967.
26. Tomhe S, Simmons RL, Tsung A. Surgery for cancer: a trigger for metastases. Cancer Res. 2017;77:1548-1552.
27. Forget P, Vandenhende J, Berliere M, et al. Do intraoperative angesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg. 2010;110:1630-1635.
28. Huang WW, Zhu WZ, Mu DL, et al. Perioperative management may improve long-term survival in patients after lung cancer surgery: a retrospective cohort study. Anesth Analg. 2018;126:1666-1674.
29. Cassinello F, Prieto I, del Olmo M, Rivas S, Strichartz GR. Cancer surgery: how may anesthesia influence outcome? J Clin Anesth. 2015;27:262-272.
30. Bugada D, Bellini V, Fanelli A, et al. Future perspectives of ERAS: a narrative review on the new applications of an established approach. Surg Res Pract. 2016;2016:3561249.
31. Hiller JG, Perry NJ, Poulogiannis G, Riedel B, Sloan EK. Perioperative events influence cancer recurrence risk after surgery. Nat Rev Clin Oncol. 2018;15:205-218.
32. Wang D, Yang XL, Chai XQ, et al. A short-term increase of the postoperative naturally circulating dendritic cells subsets in flurbiprofen-treated patients with esophageal carcinoma undergoing thoracic surgery. Oncotarget. 2016;7:18705-18712.
34. Kooltaas A, Lazaridis G, Baka S, et al. Postoperative pain management. J Thorac Dis. 2015;7:562-572.
35. Gottschalk A, Cohen SP, Yang S, Ochroch EA. Preventing and treating pain after thoracic surgery. Anesthesiology. 2006;104:594-600.
36. Ochroch EA, Gottschalk A, Augostides J, et al. Long-term pain and activity during recovery from major thoracotomy using thoracic epidural analgesia. Anesthesiology. 2002;97:1234-1244.
37. Kelsheimer B, Williams C, Kelsheimer C. New emerging modalities to treat post-thoracotomy pain syndrome: a review. Mo Med. 2019;116:41-44.
38. Gerner P. Postthoracotomy pain management problems. Anesthesiol Clin. 2008;26:355-367.
39. Karasawa F, Ehata T, Okuda T, Satoh T. Propofol injection pain is not alleviated by pretreatment with flurbiprofen axetil, a produg of a nonsteroidal antiinflammatory drug. J Anesth. 2000;14:135-137.
40. Roszkowski MT, Swilt JQ, Hargreaves KM. Effect of NSAID administration on tissue levels of immunoactive prostaglandin E2, leukotriene B4, and (S)-flurbiprofen following extraction of impacted third molars. Pain. 1997;73:339-345.
41. Phillips AW, Lagarde SM, Navidi M, Disep B, Griffin SM. Impact of extent of lymphadenectomy on survival, post neoadjuvant chemotherapy and transthoracic esophagectomy. Ann Surg. 2017;265:750-756.
42. Yamashita K, Fukusaki M, Ando Y, et al. Preoperative administration of intravenous flurbiprofen axetil reduces postoperative pain for spinal fusion surgery. J Anesth. 2006;20:92-95.
43. Tedore T. Regional anaesthesia and analgesia: relationship to cancer recurrence and survival. Br J Anaesth. 2015;115(suppl 2):i34-i45.
44. Jia R, Luan Q, Wang J, Hou D, Zhao S. Analysis of predictors for lymph node metastasis in patients with superficial esophageal carcinoma. Gastroenterol Res Pract. 2016;2016:3797615.
45. Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247:365-371.
46. Okholm C, Svendsen LB, Achiam MP. Status and prognosis of lymph node metastasis in patients with cardiac cancer—a systematic review. Surg Oncol. 2014;23:140-146.
47. Lieberman MD, Shriver CD, Bleckner S, Burt M. Carcinoma of the esophagus. Prognostic significance of histologic type. J Thorac Cardiovasc Surg. 1995;109:130-138.
48. Cho JW, Choi SC, Jang JY, et al. Lymph node metastases in esophageal carcinoma: an endoscopist’s view. Clin Endosc. 2014;47:523-529.
49. Akutsu Y, Matsubara H. The significance of lymph node status as a prognostic factor for esophageal cancer. Surg Today. 2011;41:1190-1195.
50. Zhang HL, Chen LQ, Liu RL, et al. The number of lymph node metastases influences survival and International Union Against Cancer tumor-node-metastasis classification for esophageal squamous cell carcinoma. Dis Esophagus. 2010;23:53-58.
51. Berry MF. Esophageal cancer: staging system and guidelines for staging and treatment. J Thorac Dis. 2014;6(suppl 3):S289-S297.